Venetoclax for Transplant Complications

This trial tests the safety of adding venetoclax, a medication, to the standard treatment for individuals undergoing combined stem cell and kidney transplants. The focus is on those with blood-related cancers, such as leukemia or lymphoma, who are in partial or complete remission and have a donor match. The trial aims to ensure the treatment does not cause severe side effects while supporting successful transplants. Suitable candidates have a blood-related cancer in remission, are on dialysis or have reduced kidney function, and have a matched donor relative. As an Early Phase 1 trial, this research seeks to understand how the treatment works in people, offering participants the chance to contribute to groundbreaking medical advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that venetoclax is generally safe and well-tolerated by patients. One study combined venetoclax with other treatments for patients who had undergone a stem cell transplant. The results indicated safety for these patients, with most side effects being manageable. Another study found that venetoclax provided benefits without causing serious issues, even for those at high risk of disease recurrence. While six patients died, five deaths resulted from disease recurrence and one from transplant-related complications, not directly from venetoclax. This suggests that venetoclax is a relatively safe option when used after transplants.¹²³⁴⁵

Researchers are excited about Venetoclax in the context of transplant complications because, unlike standard treatments that primarily focus on immunosuppression, Venetoclax targets and inhibits the BCL-2 protein. This protein plays a role in cell survival, and its inhibition can help eliminate problematic cells that might cause complications after a transplant. This targeted approach could potentially reduce the risk of graft-versus-host disease and improve transplant outcomes, offering a novel mechanism compared to traditional therapies.

Research has shown that venetoclax may be beneficial when combined with hematopoietic cell transplantation for certain blood cancers. In this trial, participants will receive venetoclax alongside stem cell and kidney transplants. Studies have found that venetoclax, when used with other treatments, can help treat relapsed acute myeloid leukemia (AML) following stem cell transplants. This combination does not appear to increase the risk of transplant-related complications. Additionally, venetoclax has been used successfully in treatment plans without major safety concerns. While more information is needed, early results suggest that venetoclax could effectively manage transplant-related issues.¹²⁶⁷⁸